Onsdag 2 Juli | 03:03:49 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2025-10-30 07:30 Kvartalsrapport 2025-Q3
2025-07-10 07:30 Kvartalsrapport 2025-Q2
2025-06-26 - Årsstämma
2025-05-23 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2025-04-14 - Kvartalsrapport 2025-Q1
2025-04-03 - Extra Bolagsstämma 2025
2025-02-28 - Bokslutskommuniké 2024
2024-11-05 - Kvartalsrapport 2024-Q3
2024-07-11 - Kvartalsrapport 2024-Q2
2024-06-28 - Årsstämma
2024-06-12 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2024-05-31 - Kvartalsrapport 2024-Q1
2024-02-27 - Bokslutskommuniké 2023
2023-11-02 - Kvartalsrapport 2023-Q3
2023-07-13 - Kvartalsrapport 2023-Q2
2023-07-03 - Extra Bolagsstämma 2023
2023-06-13 - Årsstämma
2023-05-24 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2023-05-04 - Kvartalsrapport 2023-Q1
2023-02-16 - Bokslutskommuniké 2022
2022-11-03 - Kvartalsrapport 2022-Q3
2022-07-14 - Kvartalsrapport 2022-Q2
2022-05-25 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2022-05-24 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-04 - Kvartalsrapport 2021-Q3
2021-07-15 - Kvartalsrapport 2021-Q2
2021-05-26 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2021-05-25 - Årsstämma
2021-05-06 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-07-16 - Kvartalsrapport 2020-Q2
2020-05-27 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2020-05-26 - Årsstämma
2020-05-07 - Kvartalsrapport 2020-Q1
2020-02-13 - Bokslutskommuniké 2019
2019-11-07 - Kvartalsrapport 2019-Q3
2019-07-18 - Kvartalsrapport 2019-Q2
2019-05-23 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2019-05-22 - Årsstämma
2019-05-03 - Kvartalsrapport 2019-Q1
2019-02-14 - Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Q-Linea är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av instrument och förbrukningsartiklar. Produkterna används huvudsakligen vid behandling av infektionssjukdomar och blodförgiftning, och innefattar diagnostik- och analysverktyg, samt grundläggande provhantering. Tekniken baseras på den så kallade ID- samt AST tekniken. Q-Linea grundades 2008 och har huvudkontor i Uppsala.
2020-11-10 10:30:00

Q-linea AB (publ) (OMX: QLINEA), today announced that the company has started the development of a portable blood culture technology with the goal of shortening the time from sampling to correct antibiotic response. The plan is to begin an external evaluation in 2021.

“Being able to start the diagnosis immediately after sampling and using the transport time for analysis instead of throwing it away feels extremely valuable. The technology means both saved hours in the workflow and enables improved and equivalent care regardless of when and where the sample is taken", says Jonas Jarvius, CEO of Q-linea.

When diagnosing patients with blood infections, the time to a correct treatment is crucial and can provide great benefits for patients, hospitals and society. In recent years, the time to obtain an answer as to which bacterium has caused the infection has been radically shortened. As bacteria show more antibiotic resistance, the need for the same change in determining which antibiotic is effective increases. Q-linea's ASTar® system will be able to provide a quick and wide response with easy operation. However, the time for transporting blood culture bottles to the microbiology labs still in many cases prolong the important time to response. In many cases, it can today take over 10 hours for a sample to arrive at the lab, depending on when and where the sample is taken, and it is only when the sample has arrived that the diagnosis can begin.

"I am proud that Q-linea's innovative technologies will really be able to make a difference for the largest critically ill patient group in healthcare. ASTar and the technology for portable blood culture could together enable a very large improvement in diagnostics. According to our calculations, the addressable market for portable blood culture bottles in Europe and the USA is approximately SEK 15 billion,” says Jonas Jarvius.

Q-linea will hold a webinar at 5 pm CET today with more information about ASTar and the portable blood culture technology. For information and registration: https://www.qlinea.com/webinar-registration